- Home
- NRT vs ATNM Comparison
NRT vs ATNM Comparison
Compare NRT & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- ATNM
- Stock Information
- Founded
- NRT 1975
- ATNM 2000
- Country
- NRT United States
- ATNM United States
- Employees
- NRT N/A
- ATNM N/A
- Industry
- NRT Oil & Gas Production
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- NRT Energy
- ATNM Health Care
- Exchange
- NRT Nasdaq
- ATNM Nasdaq
- Market Cap
- NRT 46.4M
- ATNM 50.2M
- IPO Year
- NRT N/A
- ATNM N/A
- Fundamental
- Price
- NRT $5.17
- ATNM $1.67
- Analyst Decision
- NRT
- ATNM Strong Buy
- Analyst Count
- NRT 0
- ATNM 2
- Target Price
- NRT N/A
- ATNM $4.50
- AVG Volume (30 Days)
- NRT 40.7K
- ATNM 123.5K
- Earning Date
- NRT 08-29-2025
- ATNM 11-13-2025
- Dividend Yield
- NRT 9.28%
- ATNM N/A
- EPS Growth
- NRT 24.05
- ATNM N/A
- EPS
- NRT 0.59
- ATNM N/A
- Revenue
- NRT $6,184,173.00
- ATNM N/A
- Revenue This Year
- NRT N/A
- ATNM N/A
- Revenue Next Year
- NRT N/A
- ATNM N/A
- P/E Ratio
- NRT $8.88
- ATNM N/A
- Revenue Growth
- NRT 18.55
- ATNM N/A
- 52 Week Low
- NRT $3.88
- ATNM $1.03
- 52 Week High
- NRT $5.75
- ATNM $2.41
- Technical
- Relative Strength Index (RSI)
- NRT 47.79
- ATNM 50.97
- Support Level
- NRT $4.90
- ATNM $1.61
- Resistance Level
- NRT $5.39
- ATNM $1.70
- Average True Range (ATR)
- NRT 0.16
- ATNM 0.07
- MACD
- NRT 0.00
- ATNM -0.01
- Stochastic Oscillator
- NRT 55.10
- ATNM 51.79
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.